Silence Therapeutics to Participate in Three September Investor Conferences

Silence Therapeutics (SLN) will participate in three healthcare investor conferences in September 2026, each featuring a fireside chat with company management.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following conferences and invited investors to participate by webcast.

• Cantor Global Healthcare Conference 2026
  Fireside chat on Wednesday, September 9, 2026 at 10:55 a.m. ET

• H.C. Wainwright 28th Annual Global Investment Conference
  Fireside chat on Tuesday, September 15, 2026 at 3:00 p.m. ET

• Morgan Stanley 24th Annual Global Healthcare Conference
  Fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. ET

The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com/events. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https://www.silence-therapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260902345520/en/

Inquiries:
Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc

Key Terms

sirna medical

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.